

**AMENDMENTS TO THE CLAIMS**

1. **(Currently Amended)** An implant for treating a medical condition of an eye, the implant comprising:
  - (a) a carrier, and;
  - (b) a botulinum neurotoxin complex having a molecular weight of about 900 kD, 700, kD, 500 kD or 300 kD, associated with the carrier, thereby forming an implant, wherein a therapeutic amount of the botulinum neurotoxin can be released from the carrier upon implantation of the implant into a patient to thereby treat a medical condition of an eye.
- 2.-3 **(Cancelled)**
4. **(Previously Presented)** The implant of claim 1, wherein the carrier is substantially biodegradable.
5. **(Previously Presented)** The implant of claim 1 wherein the botulinum neurotoxin is selected from the group consisting of botulinum neurotoxin serotypes A, B, C, D, E, F and G..
6. -7. **(Cancelled)**
8. **(Currently Amended)** A method for treating a condition of the eye, the method comprising the step of implanting into a patient a biodegradable implant comprising a botulinum neurotoxin complex having a molecular weight of about 900 kD, 700, kD, 500 kD or 300 kD associated with a carrier.
- 9.-13 **(Cancelled)**
14. **(New)** An implant for treating a medical condition of an eye, the implant comprising:
  - (a) a carrier, and;

(b) a botulinum type A neurotoxin complex, having a molecular weight of about 900 kD, associated with the carrier, thereby forming an implant, wherein a therapeutic amount of the botulinum neurotoxin can be released from the carrier upon implantation of the implant into a patient to thereby treat a medical condition of an eye